Continuous Glucose Metrics for Prediabetes Detection

Abstract

Prediabetes is a prevalent metabolic condition that significantly elevates the risk of type 2 diabetes mellitus (T2DM) and cardiovascular complications. Early and accurate identification of prediabetes is crucial for timely intervention and prevention of disease progression. Continuous glucose monitoring (CGM) systems have emerged as a promising tool for capturing dynamic glucose profiles beyond traditional static markers like fasting glucose and HbA1c. This review evaluates current evidence on the clinical utility, mechanistic basis, and practical implications of continuous glucose metrics in the detection of prediabetes, focusing on recent advances and guideline recommendations relevant to healthcare professionals.

Introduction

Prediabetes, characterized by glycemic values above normal but below the diabetic threshold, affects an estimated 38% of adults globally and poses a significant clinical challenge. The conventional diagnostic criteria impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and elevated HbA1c often miss subtle glucose excursions and may underestimate glycemic risk. The advent of continuous glucose monitoring (CGM) has revolutionized the assessment of glycemic patterns, providing granular insights into glucose fluctuations that static measurements cannot capture. Understanding the application of continuous glucose metrics for prediabetes detection holds substantial promise for enhancing risk stratification, individualized care, and early prevention of T2DM.

Epidemiology / Disease Burden

Prediabetes represents a major global health burden, with the International Diabetes Federation estimating over 470 million cases by 2030. In the United States, the Centers for Disease Control and Prevention reports that more than 96 million adults over one-third of the population meet criteria for prediabetes. The transition rate from prediabetes to T2DM is approximately 5-10% per year, with a cumulative risk of up to 70% over a lifetime. Importantly, prediabetes itself is associated with increased risk of cardiovascular disease, microvascular complications, and all-cause mortality, underscoring the clinical urgency for improved diagnostic modalities and early intervention strategies.

Pathophysiology

The pathophysiology of prediabetes involves a complex interplay between insulin resistance, β-cell dysfunction, and aberrant glucose homeostasis. In the early stages, peripheral tissues especially skeletal muscle and adipose develop diminished responsiveness to insulin, necessitating compensatory hyperinsulinemia. Over time, pancreatic β-cells fail to maintain adequate insulin secretion, resulting in progressive dysglycemia. Episodic postprandial hyperglycemia and increased glycemic variability are key features often missed by isolated fasting or average glucose measurements. CGM enables real-time assessment of these dynamic aberrations, offering mechanistic insight into early metabolic dysfunction.

Risk Factors

Major risk factors for prediabetes include obesity (particularly central adiposity), family history of diabetes, sedentary lifestyle, advancing age, and certain ethnic backgrounds (e.g., African American, Hispanic, Native American, Asian). Additional contributors encompass gestational diabetes history, polycystic ovary syndrome, dyslipidemia, and hypertension. These risk factors potentiate insulin resistance and β-cell dysfunction, accelerating the path to overt diabetes. Identification of at-risk individuals remains a cornerstone for targeted screening and prevention.

Clinical Features

Prediabetes is generally asymptomatic, but subtle clinical manifestations may include mild polyuria or polydipsia, fatigue, and signs of metabolic syndrome such as acanthosis nigricans. The absence of overt symptoms necessitates proactive screening in high-risk populations. Importantly, the lack of symptoms does not preclude ongoing vascular and metabolic injury, further justifying the need for sensitive detection methods.

Diagnosis

Traditional diagnostic modalities encompass fasting plasma glucose (100-125 mg/dL), 2-hour glucose in oral glucose tolerance test (OGTT) (140-199 mg/dL), and HbA1c (5.7%-6.4%). However, these static tests may fail to detect intermittent hyperglycemia and glycemic variability. CGM systems, by continuously measuring interstitial glucose every 1-5 minutes, provide comprehensive metrics such as time-in-range (TIR), mean glucose, glycemic excursions, and coefficient of variation. Studies have demonstrated that individuals with prediabetes exhibit increased time above range (TAR), higher glycemic variability, and abnormal postprandial glucose spikes, which are strong predictors of future diabetes risk. Incorporating CGM-derived metrics into diagnostic algorithms may facilitate earlier identification and intervention.

Treatment & Management

Lifestyle modification comprising dietary changes, weight reduction, and increased physical activity remains the first-line intervention for prediabetes. Pharmacological agents like metformin may be indicated in high-risk individuals, particularly those with BMI ≥35 kg/m², age <60, or women with prior gestational diabetes. CGM-guided personalized feedback has shown promise in enhancing patient engagement, supporting dietary adherence, and optimizing glycemic targets. Early detection via CGM allows for tailored interventions aimed at minimizing glycemic variability and halting progression to T2DM.

Recent Advances / Emerging Therapies

Technological advancements in CGM have yielded minimally invasive, highly accurate, and user-friendly devices suitable for non-diabetic populations. Emerging research highlights novel CGM-derived metrics such as glucose peak width, postprandial area under the curve (AUC), and glycemic variability indices as superior predictors of metabolic risk compared to traditional measures. Integration of CGM data with artificial intelligence and machine learning algorithms may further refine risk prediction and enable precision prevention. Additionally, ongoing trials are investigating the impact of CGM-informed lifestyle coaching on long-term glycemic outcomes in prediabetes.

Guideline Recommendations

While current ADA and EASD guidelines primarily reserve CGM for individuals with established diabetes, recent position statements acknowledge its potential value in high-risk and prediabetic populations, especially for research and lifestyle intervention studies. The International Consensus on Time in Range has called for further validation of CGM thresholds specific to prediabetes. Clinicians are encouraged to consider CGM in selected at-risk patients, particularly where standard tests yield equivocal results or where granular glycemic data may guide therapeutic decisions.

Conclusion

Continuous glucose metrics represent a paradigm shift in the detection and management of prediabetes, offering unprecedented insight into early metabolic dysregulation. By capturing real-time glycemic patterns and variability, CGM enables more sensitive and individualized risk assessment than traditional static markers. Integration of CGM into clinical practice, supported by emerging evidence and evolving guidelines, may significantly enhance early identification, patient engagement, and effective prevention of T2DM. Ongoing research will further elucidate optimal CGM-based thresholds and strategies for prediabetes detection, ultimately informing best practice in metabolic disease prevention.